TSP TruSpine Technologies Plc

TIDMTSP

RNS Number : 6547M

TruSpine Technologies PLC

18 September 2023

18 September 2023

TruSpine Technologies plc

("TruSpine" or the "Company")

Proposed Director Appointments & Update

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused on the development of its pioneering "screwless," spinal (vertebral) stabilisation systems announces the proposed appointments of Victoria Sena and Samuel Ogunsalu as Non-Executive Directors of the Company, subject to standard regulatory due diligence.

Proposed Director Appointments

Victoria Sena founded Cherrybank Consulting Limited in 2019 to assist clients in the areas of governance, operations, risk, and compliance. Previously Victoria spent eight years at the Bank of England in the authorisations, banking, and insurance divisions, and completed a secondment to the Treasury Committee of the House of Commons. After moving to the private sector Victoria served as a Group Risk Manager for an international insurance group, before becoming Chief Operating Officer of a boutique investment manager where she was an FCA Approved Person. She is a Chartered Member of the Chartered Institute of Securities and Investments and holds degrees from Oxford University and the London School of Economics and Political Science.

Samuel Ogunsalu has over 20 years' experience in technology commercialisation, licensing, and business development. He has executed a wide number of transactions ranging from negotiating licences and M&As, to transformational technology partnerships with companies such as Merck, GSK, Pharmacia (merged with Pfizer) and Abbott (now AbbVie) as well as helping to establish preclinical research programmes with a number of industrial partners and set up joint ventures, start-ups, and spinout companies to develop novel technologies. Samuel was previously Chief Business Officer & Director of an oncology company and Chief Commercial Officer of an AIM listed biotech company. Prior to that he has held a number of positions across technology business units connected with Queen Mary College, London, as well as other roles in which he has advised private and listed companies in both the UK and the USA. He started his professional career as a pilot plant engineer at Imperial College, London, followed by scientific research at University College London, before moving into business & commercial development. Samuel holds a BSc in Microbiology from the University of Wales, and an MSc in Biochemical Engineering from UCL.

A further announcement will be made in due course following completion of standard regulatory due diligence.

Update

Further to the announcement of 17 August 2023, the Company announces that it will not appeal the Disciplinary Notice published by the Aquis Stock Exchange which resulted from the Aquis Disciplinary Investigation. The Company accepts the findings of the Aquis Disciplinary Investigation.

The Company believes that the appointments of Victoria Sena and Samuel Ogunsalu will improve the corporate governance at the Company.

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement of 17 August 2023.

The Directors of the Company are responsible for the release of this announcement.

Enquiries:

 
 TruSpine Technologies Plc                                   Tel: +44 (0)20 7118 0852 
 Laurence Strauss, Chief Executive Officer 
 
 Cairn Financial Advisers LLP (AQSE Corporate Adviser)       Tel: +44 (0)20 7213 0880 
 Liam Murray / Ludovico Lazzaretti 
 Peterhouse Capital Limited (Broker & Financial Adviser) 
                                                             Tel: +44 (0)20 7469 0930 
 Lucy Williams / Duncan Vasey 
 Novus Communications (PR and IR)                            Tel: +44 (0)20 7448 9839 
 Alan Green / Jacqueline Briscoe                              novuscomms@truspine.org 
 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identi ed by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements re ect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXGPUPWBUPWGWA

(END) Dow Jones Newswires

September 18, 2023 02:00 ET (06:00 GMT)

TruSpine Technologies (AQSE:TSP)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024

TruSpine Technologies (AQSE:TSP)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024